Seeking New Antidepressant Agents
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 69006
Special Issue Editor
Interests: depression; cognition; biased agonists; drug discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Major depressive disorder affects more than 300 million people of all ages around the world. According to the World Health Organization, depression is a significant risk factor for suicide, accounting for up to 0.5 million suicides yearly. Moreover, the recent coronavirus disease 2019 (COVID-19) pandemic has seriously impacted public mental health and caused a rapid rise in depressed patients. Unfortunately, the available antidepressants are effective in only around one-third of depressed individuals, leaving the vast majority of patients inadequately treated. Besides, the clinical effects of most drugs appear after 2–4 weeks of treatment, which dramatically increases the risk of suicide. Thus, the development of new rapidly acting antidepressants is of utmost importance. Various compounds have proven successful in treating depression and may inspire further investigation for the development of new antidepressant molecules.
With this Special Issue, we would like to bring together experts working in the field of depression and invite them to present their recent results related to all aspects of drug discovery and development. We will also welcome review articles and short communications on the latest achievements in this field.
Dr. Karolina Pytka
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- serotonin and noradrenaline reuptake inhibitors (SNRIs)
- selective serotonin reuptake inhibitors (SSRIs)
- tricyclic antidepressants (TCAs)
- monoamine oxidase inhibitors (MAOIs)
- noradrenaline and specific serotoninergic antidepressants (NASSAs)
- atypical antidepressants
- drug discovery
- preclinical studies
- clinical studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.